// App-Quantinova.ai

412 : Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies

Researchers

Presenter

  • Maureen Dubreuil

Principal Investigators

  • Karl Gaffney

  • Lianne Gensler

  • Jonathan Kay

  • Victoria Navarro-Compán

  • Christine de la Loge

  • Alicia Ellis

  • Carmen Fleurinck

  • Marga Oortgiesen

  • Vanessa Taieb

  • Atul Deodhar

Medical Centers

  • Department of Medicine, Boston University School of Medicine, Boston, MA

  • Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom.

  • Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Franciso, California, United States

  • Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA

  • Department of Hematology, La Paz University Hospital‐IdiPaz, Madrid

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Raleigh, NC

  • UCB Pharma, Brussels, Belgium, Oosterzele, Belgium

  • UCB Pharma, Raleigh, NC

  • UCB Pharma, Colombes, France

  • Oregon Health & Science University, Portland, OR, USA, Portland, OR

Locations

  • United States

  • United Kingdom

  • Spain

  • Belgium

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT03928704

  • NCT03928743

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved